Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma

Junli Yan, Boheng Li, Baohong Lin, Pei Tsung Lee, Tae-Hoon Chung, Joy Tan, Chonglei Bi, Xue Ting Lee, Viknesvaran Selvarajan, Siok-Bian Ng, Henry Yang, Qiang Yu, Wee-Joo Chng

Blood (2016) 128 (7): 948–958.

https://doi.org/10.1182/blood-2016-01-690701

Published: 2016

Includes: Supplemental data

Journal Articles

Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells

Niels Franke, MD, Gertjan J.L. Kaspers, MD PhD, Yehuda G Assaraf, PhD, Johan Van Meerloo, MSc, Denise Niewerth, PhD, Terzah M. Horton, MD PhD, Wee Joo Chng, MD PhD, Chonglei Bi, B.S, Rene X. Menezes, PhD, Renée J. Musters, PhD, Pino J. Poddighe, PhD, Floortje Kessler, Serge Smeets, PhD, Bauke Ylstra, PhD, Sonja Zweegman, MD PhD, Gerrit Jansen, PhD, Jacqueline Cloos, PhD

Blood (2015) 126 (23): 3712.

https://doi.org/10.1182/blood.V126.23.3712.3712

Published: 2015

Journal Articles

PRIMA-1 (p53 Reactivation and Induction of Massive Apoptosis) Mediates Anti-Myeloma Effect through the ER Stress Pathway

Phaik Ju Teoh, Chonglei Bi, Sinto Sebastian, PhD, Rafael Fonseca, MD, Wee Joo Chng, MD PhD

Blood (2014) 124 (21): 2093.

https://doi.org/10.1182/blood.V124.21.2093.2093

Published: 2014

Journal Articles

MMSET Regulates IRF4, a Transcription Factor Critical for the Survival of T(4;14) Myeloma Myeloma Cells, and Its Silence Potentiates the Effect of Antimyeloma Agents

Zhigang Xie, PhD, Chonglei Bi, B.S, Jing Yuan Chooi, B.S, Zit Liang Chan, B.S, Nurulhuda Mustafa, PhD, Wee Joo Chng, MD PhD

Blood (2014) 124 (21): 171.

https://doi.org/10.1182/blood.V124.21.171.171

Published: 2014

Journal Articles

EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity

Junli Yan, Siok-Bian Ng, Jim Liang-Seah Tay, Baohong Lin, Tze Loong Koh, Joy Tan, Viknesvaran Selvarajan, Shaw-Cheng Liu, Chonglei Bi, Shi Wang, Shoa-Nian Choo, Norio Shimizu, Gaofeng Huang, Qiang Yu, Wee-Joo Chng

Blood (2013) 121 (22): 4512–4520.

https://doi.org/10.1182/blood-2012-08-450494

Published: 2013

Includes: Supplemental data

Journal Articles

EZH2 Is Aberrantly Expressed and Plays a Pro-Proliferative Role Independent of Its Methyltransferase Activity in Natural Killer/T-Cell Lymphoma

Wee-Joo Chng, Assoc/Prof, Junli Yan, PhD, Siok-Bian NG, Jim Tay, Ph.D., Baohong Lin, BSc, Tze-Loong Koh, B.sc., Joy Tan, BSc, Viknesvaran Selvarajan, Shaw-Cheng Liu, B.sc., Chonglei Bi, B.sc., Gaofeng Huang, PhD, Qiang Yu, Ph.D.

Blood (2012) 120 (21): 3498.

https://doi.org/10.1182/blood.V120.21.3498.3498

Published: 2012

Journal Articles

The Pro-Metastasis Tyrosine Phosphatase, PRL-3 ( PTP4A3 ), Is a Novel Target of BCR-ABL Signaling Involved in Human Chronic Myeloid Leukemia

Jianbiao Zhou, M.D., Ph.D., Lip-Lee Cheong, B.sc., Sylvia Mahara, B.sc., Shaw-Cheng Liu, B.sc., Phyllis SY Chong, B.sc., Chonglei Bi, B.sc., Tze-Loong Koh, B.sc., Kelly OK Ong, B.sc., Qi Zeng, Ph.D., Wee-Joo Chng, MRCP, MRCPath

Blood (2011) 118 (21): 2741.

https://doi.org/10.1182/blood.V118.21.2741.2741

Published: 2011

Journal Articles

Dysregulated MicroRNA Affects Pathways and Targets of Biological Relevance in Nasal-Type Natural Killer/T-Cell Lymphoma

Wee-Joo Chng, M.B.Ch.B, Junli Yan, PhD, Gaofeng Huang, PhD, Viknesvaran Selvarajan, BSc, Jim Tay, BSc, Baohong Lin, BSc, Chonglei Bi, B.sc., Joy Tan, BSc, Siok-Bian Ng, MB ChB

Blood (2011) 118 (21): 2637.

https://doi.org/10.1182/blood.V118.21.2637.2637

Published: 2011

Journal Articles

Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma

Siok-Bian Ng, Junli Yan, Gaofeng Huang, Viknesvaran Selvarajan, Jim Liang-Seah Tay, Baohong Lin, Chonglei Bi, Joy Tan, Yok-Lam Kwong, Norio Shimizu, Katsuyuki Aozasa, Wee-Joo Chng

Blood (2011) 118 (18): 4919–4929.

https://doi.org/10.1182/blood-2011-07-364224

Published: 2011

Includes: Supplemental data

Journal Articles

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML

Jianbiao Zhou, Chonglei Bi, Lip-Lee Cheong, Sylvia Mahara, Shaw-Cheng Liu, Kian-Ghee Tay, Tze-Loong Koh, Qiang Yu, Wee-Joo Chng

Blood (2011) 118 (10): 2830–2839.

https://doi.org/10.1182/blood-2010-07-294827

Published: 2011

Includes: Supplemental data

Journal Articles

The Histone Methyltransferase Inhibitor, DZNep, Upregulates TXNIP, Increases ROS Production and Targets Leukemia Cells In AML

Jianbiao Zhou, M.D., Ph.D., Chonglei Bi, B.sc., Shaw-Cheng Liu, Kian-Ghee Tay, Lip-Lee Cheong, B.sc., Tze-Loong Koh, B.sc., Qiang Yu, Ph.D., Wee-Joo Chng, MRCP, MRCPath

Blood (2010) 116 (21): 4355.

https://doi.org/10.1182/blood.V116.21.4355.4355

Published: 2010

Journal Articles

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

Jianbiao Zhou, Chonglei Bi, Jasinghe V. Janakakumara, Shaw-Cheng Liu, Wee-Joo Chng, Kian-Ghee Tay, Lai-Fong Poon, Zhigang Xie, Senthilnathan Palaniyandi, Hanry Yu, Keith B. Glaser, Daniel H. Albert, Steven K. Davidsen, Chien-Shing Chen

Blood (2009) 113 (17): 4052–4062.

https://doi.org/10.1182/blood-2008-05-156422

Published: 2009

Includes: Supplemental data

Journal Articles

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Jianbiao Zhou, MD, MS, Chonglei Bi, Bsc, Shaw-Cheng Liu, Wee-Joo Chng, MD, Kian-Ghee Tay, Bsc, Hanry Yu, Ph.D., Keith Glaser, Ph.D., Daniel Albert, PhD, BSc, Steven K Davidsen, Ph.D., Chien-Shing Chen, MD, PhD

Blood (2008) 112 (11): 1618.

https://doi.org/10.1182/blood.V112.11.1618.1618

Published: 2008

Journal Articles

Overactivation of STAT Pathways and Overexpression of Survivin Confer Resistance to FLT3 Inhibitors and Could Be Therapeutic Targets in AML.

Jianbiao Zhou, MD, MSc, Chonglei Bi, B.S., Lai Fong Poon, B.S., Viraj J. Janakakumara, B.S., Jiaying Khng, Hanry Yu, Ph.D., Keith B. Glaser, Ph.D., Daniel H. Albert, Ph.D., Davidsen K. Davidsen, Ph.D., Chien-Shing Chen, Ph.D.

Blood (2007) 110 (11): 2367.

https://doi.org/10.1182/blood.V110.11.2367.2367

Published: 2007

NARROW

EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma

Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells

PRIMA-1 (p53 Reactivation and Induction of Massive Apoptosis) Mediates Anti-Myeloma Effect through the ER Stress Pathway

MMSET Regulates IRF4, a Transcription Factor Critical for the Survival of T(4;14) Myeloma Myeloma Cells, and Its Silence Potentiates the Effect of Antimyeloma Agents

EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity

EZH2 Is Aberrantly Expressed and Plays a Pro-Proliferative Role Independent of Its Methyltransferase Activity in Natural Killer/T-Cell Lymphoma

The Pro-Metastasis Tyrosine Phosphatase, PRL-3 ( PTP4A3 ), Is a Novel Target of BCR-ABL Signaling Involved in Human Chronic Myeloid Leukemia

Dysregulated MicroRNA Affects Pathways and Targets of Biological Relevance in Nasal-Type Natural Killer/T-Cell Lymphoma

Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML

The Histone Methyltransferase Inhibitor, DZNep, Upregulates TXNIP, Increases ROS Production and Targets Leukemia Cells In AML

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Overactivation of STAT Pathways and Overexpression of Survivin Confer Resistance to FLT3 Inhibitors and Could Be Therapeutic Targets in AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only